A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
Study of Etavopivat in Patients with Myelodysplastic Syndromes (MDS)
Sponsor: Forma Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU3328
U.S. Govt. ID: NCT05568225
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the effects of etavopivat, good and bad, in individuals with myelodysplastic syndrome (MDS).
Joseph Jurcic, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2? Yes No
Can you comply with the procedures in this study, which include taking the study drug and extra clinic visits and procedures? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator